Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 8.01 (Other Events). ERAS-0015 delivered 57% 8-week uORR in 2L+ KRAS G12X PDAC at 32 mg QD, based on 7 patients.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ERAS-0015 delivered 57% 8-week uORR in 2L+ KRAS G12X PDAC at 32 mg QD, based on 7 patients
- Treatment persistence strong: 6 of 7 patients remained on treatment at 32 mg and 6 of 8 at 24 mg
- Safety mostly low-grade, but one Grade 3 pneumonitis progressed to Grade 5 after supportive-care withdrawal
- Rash affected 72% of 72 patients; dose interruptions 13%, reductions 8%, and discontinuations 0%
- Development accelerates toward registration-enabling NSCLC and Phase 3 PDAC trials beginning in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.